Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
VNDA's Cash to Debt is ranked higher than
91% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. VNDA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
VNDA' s Cash to Debt Range Over the Past 10 Years
Min: 209.57  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.66
VNDA's Equity to Asset is ranked lower than
53% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. VNDA: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
VNDA' s Equity to Asset Range Over the Past 10 Years
Min: 0.01  Med: 0.17 Max: 0.94
Current: 0.66
0.01
0.94
Interest Coverage No Debt
VNDA's Interest Coverage is ranked higher than
87% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VNDA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VNDA' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: 2.74
M-Score: 0.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 47.52
VNDA's Operating margin (%) is ranked higher than
95% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. VNDA: 47.52 )
Ranked among companies with meaningful Operating margin (%) only.
VNDA' s Operating margin (%) Range Over the Past 10 Years
Min: -790.41  Med: -48.41 Max: 40
Current: 47.52
-790.41
40
Net-margin (%) 47.78
VNDA's Net-margin (%) is ranked higher than
96% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. VNDA: 47.78 )
Ranked among companies with meaningful Net-margin (%) only.
VNDA' s Net-margin (%) Range Over the Past 10 Years
Min: -788.46  Med: -46.75 Max: 40.25
Current: 47.78
-788.46
40.25
ROE (%) 36.60
VNDA's ROE (%) is ranked higher than
97% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. VNDA: 36.60 )
Ranked among companies with meaningful ROE (%) only.
VNDA' s ROE (%) Range Over the Past 10 Years
Min: -246.18  Med: -91.29 Max: 23.67
Current: 36.6
-246.18
23.67
ROA (%) 24.57
VNDA's ROA (%) is ranked higher than
97% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. VNDA: 24.57 )
Ranked among companies with meaningful ROA (%) only.
VNDA' s ROA (%) Range Over the Past 10 Years
Min: -176.39  Med: -21.71 Max: 12.81
Current: 24.57
-176.39
12.81
ROC (Joel Greenblatt) (%) 1115.60
VNDA's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. VNDA: 1115.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VNDA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4620.09  Med: -2021.63 Max: 784.55
Current: 1115.6
-4620.09
784.55
Revenue Growth (3Y)(%) 7.30
VNDA's Revenue Growth (3Y)(%) is ranked higher than
59% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. VNDA: 7.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VNDA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 89.7
Current: 7.3
0
89.7
» VNDA's 10-Y Financials

Financials (Next Earnings Date: 2016-02-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

VNDA Guru Trades in Q4 2014

John Paulson 3,625,000 sh (+11.54%)
» More
Q1 2015

VNDA Guru Trades in Q1 2015

Paul Tudor Jones 25,000 sh (New)
Jim Simons 195,100 sh (New)
John Paulson 3,950,000 sh (+8.97%)
» More
Q2 2015

VNDA Guru Trades in Q2 2015

Steven Cohen 96,500 sh (New)
Jim Simons Sold Out
John Paulson 3,946,500 sh (-0.09%)
Paul Tudor Jones 21,194 sh (-15.22%)
» More
Q3 2015

VNDA Guru Trades in Q3 2015

Paul Tudor Jones 40,776 sh (+92.39%)
John Paulson 3,946,500 sh (unchged)
Steven Cohen 1,900 sh (-98.03%)
» More
» Details

Insider Trades

Latest Guru Trades with VNDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 8.42
VNDA's P/E(ttm) is ranked higher than
88% of the 372 Companies
in the Global Biotechnology industry.

( Industry Median: 29.14 vs. VNDA: 8.42 )
Ranked among companies with meaningful P/E(ttm) only.
VNDA' s P/E(ttm) Range Over the Past 10 Years
Min: 8.42  Med: 29.88 Max: 217.54
Current: 8.42
8.42
217.54
Forward P/E 7.94
VNDA's Forward P/E is ranked higher than
81% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 16.75 vs. VNDA: 7.94 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 8.42
VNDA's PE(NRI) is ranked higher than
88% of the 272 Companies
in the Global Biotechnology industry.

( Industry Median: 31.25 vs. VNDA: 8.42 )
Ranked among companies with meaningful PE(NRI) only.
VNDA' s PE(NRI) Range Over the Past 10 Years
Min: 8.42  Med: 28.27 Max: 214.43
Current: 8.42
8.42
214.43
P/B 2.35
VNDA's P/B is ranked higher than
54% of the 1123 Companies
in the Global Biotechnology industry.

( Industry Median: 2.60 vs. VNDA: 2.35 )
Ranked among companies with meaningful P/B only.
VNDA' s P/B Range Over the Past 10 Years
Min: 2.35  Med: 6.18 Max: 540.33
Current: 2.35
2.35
540.33
P/S 3.68
VNDA's P/S is ranked higher than
76% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. VNDA: 3.68 )
Ranked among companies with meaningful P/S only.
VNDA' s P/S Range Over the Past 10 Years
Min: 2.62  Med: 6.63 Max: 69.06
Current: 3.68
2.62
69.06
POCF 799.00
VNDA's POCF is ranked lower than
97% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 25.81 vs. VNDA: 799.00 )
Ranked among companies with meaningful POCF only.
VNDA' s POCF Range Over the Past 10 Years
Min: 0.96  Med: 1.69 Max: 1409
Current: 799
0.96
1409
EV-to-EBIT 4.44
VNDA's EV-to-EBIT is ranked higher than
78% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 20.78 vs. VNDA: 4.44 )
Ranked among companies with meaningful EV-to-EBIT only.
VNDA' s EV-to-EBIT Range Over the Past 10 Years
Min: -1288.6  Med: 0.80 Max: 578.2
Current: 4.44
-1288.6
578.2
EV-to-EBITDA 3.56
VNDA's EV-to-EBITDA is ranked higher than
81% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 17.31 vs. VNDA: 3.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
VNDA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.8  Med: 0.95 Max: 81.6
Current: 3.56
-20.8
81.6
Current Ratio 3.79
VNDA's Current Ratio is ranked lower than
55% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. VNDA: 3.79 )
Ranked among companies with meaningful Current Ratio only.
VNDA' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 4.92 Max: 18.62
Current: 3.79
1.67
18.62
Quick Ratio 3.71
VNDA's Quick Ratio is ranked lower than
53% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. VNDA: 3.71 )
Ranked among companies with meaningful Quick Ratio only.
VNDA' s Quick Ratio Range Over the Past 10 Years
Min: 1.64  Med: 4.92 Max: 18.62
Current: 3.71
1.64
18.62
Days Inventory 81.88
VNDA's Days Inventory is ranked higher than
67% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. VNDA: 81.88 )
Ranked among companies with meaningful Days Inventory only.
VNDA' s Days Inventory Range Over the Past 10 Years
Min: 151.44  Med: 228.63 Max: 596.04
Current: 81.88
151.44
596.04
Days Sales Outstanding 61.67
VNDA's Days Sales Outstanding is ranked higher than
53% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. VNDA: 61.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
VNDA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.22  Med: 20.39 Max: 253.93
Current: 61.67
5.22
253.93
Days Payable 33.12
VNDA's Days Payable is ranked lower than
68% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. VNDA: 33.12 )
Ranked among companies with meaningful Days Payable only.
VNDA' s Days Payable Range Over the Past 10 Years
Min: 81.81  Med: 327.28 Max: 812.05
Current: 33.12
81.81
812.05

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.90
VNDA's Price/Net Cash is ranked higher than
56% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 18.00 vs. VNDA: 4.90 )
Ranked among companies with meaningful Price/Net Cash only.
VNDA' s Price/Net Cash Range Over the Past 10 Years
Min: 0.31  Med: 8.21 Max: 1625
Current: 4.9
0.31
1625
Price/Net Current Asset Value 3.44
VNDA's Price/Net Current Asset Value is ranked higher than
64% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. VNDA: 3.44 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VNDA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.3  Med: 7.85 Max: 185
Current: 3.44
0.3
185
Price/Tangible Book 3.29
VNDA's Price/Tangible Book is ranked higher than
57% of the 1051 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. VNDA: 3.29 )
Ranked among companies with meaningful Price/Tangible Book only.
VNDA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.29  Med: 6.55 Max: 392
Current: 3.29
0.29
392
Price/Median PS Value 0.55
VNDA's Price/Median PS Value is ranked higher than
74% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. VNDA: 0.55 )
Ranked among companies with meaningful Price/Median PS Value only.
VNDA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 1.03 Max: 9.96
Current: 0.55
0.48
9.96
Price/Graham Number 1.11
VNDA's Price/Graham Number is ranked higher than
72% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. VNDA: 1.11 )
Ranked among companies with meaningful Price/Graham Number only.
VNDA' s Price/Graham Number Range Over the Past 10 Years
Min: 1.56  Med: 3.46 Max: 11.71
Current: 1.11
1.56
11.71
Earnings Yield (Greenblatt) (%) 22.51
VNDA's Earnings Yield (Greenblatt) (%) is ranked higher than
93% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. VNDA: 22.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VNDA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 24.10 Max: 3521.3
Current: 22.51
0.2
3521.3

More Statistics

Revenue(Mil) $93
EPS $ 0.95
Beta1.69
Short Percentage of Float19.68%
52-Week Range $7.73 - 14.50
Shares Outstanding(Mil)42.82

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 109 155 202 262
EPS($) -0.57 -0.11 1.01 2.36
EPS without NRI($) -0.57 -0.11 1.01 2.36

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VM4.Germany,
Vanda Pharmaceuticals Inc was incorporated in Delaware in 2002 and began operations in March 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. It operates in one business segment which is the development and commercialization of pharmaceutical products. Its product portfolio includes: HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder, which was approved by the U.S. FDA in January 2014; Fanapt, a product for the treatment of schizophrenia, the oral formulation of which is currently being marketed and sold in the U.S. by Novartis Pharma AG; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The Company utilizes a virtual supply manufacturing and distribution chain in which it does not have its own facilities to manufacture commercial or clinical trial supplies of drugs and does not have its own distribution facilities.
» More Articles for VNDA

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Vanda Pharmaceuticals Inc. (VNDA) Acting CFO/Treasurer Stephanie Rast Irish sells 20,000 Shares Feb 23 2010 
Preserving Value: The Case for Voluntary Liquidation Jan 17 2010 

More From Other Websites
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 04 2016
Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day Feb 01 2016
Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day Feb 01 2016
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February... Jan 22 2016
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February... Jan 22 2016
Edited Transcript of VNDA earnings conference call or presentation 19-Feb-15 3:00pm GMT Jan 19 2016
Biotechnology Equities Scrutiny -- Advaxis, Raptor Pharma, Vanda Pharma, and Infinity Pharma Jan 14 2016
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 Results and 2016... Jan 11 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 11 2016
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 Results and 2016... Jan 11 2016
Innovation Sparks Advancement of New Treatments for Atopic Dermatitis Jan 07 2016
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 31,... Dec 31 2015
Biotechnology Equities Ahead of Market -- Regulus Therapeutics, Ocata Therapeutics, Vanda Pharma,... Dec 30 2015
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 22 2015
European Medicines Agency Accepts Fanaptum® (iloperidone) Marketing Authorization Application for... Dec 22 2015
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments... Dec 21 2015
Vanda Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
Equities Lead Investor Sentiment - Free Research on NOW, Vanda Pharmaceuticals, Inovalon Holdings... Dec 21 2015
5 Stocks Insiders Love for 2016 Dec 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK